Kidney Disease
163
33-48 of 148
- Tackling the risk of hyperkalemia through guideline-recommended heart failure therapyThe key role of RAASi therapy in patients with HF
Shelley Zieroth, MD
- Tackling the risk of hyperkalemia through guideline-recommended heart failure therapyPrescribing and monitoring novel potassium binders for optimizing RAASi therapy in HF
Aaron Wong, MD
- ESC Congress 2023Inorganic nitrate reduces risk of contrast-induced nephropathy after coronary angiography
Dan Jones, MD, PhD
Theresa McDonagh, MD
Nikolaus Marx, MD
Milton Packer, MD
Muthiah Vaduganathan, MD
Tessa Laubscher, MD
George L. Bakris, MD
Mikhail Kosiborod, MD
Tessa Laubscher, MD
George L. Bakris, MD
Mikhail Kosiborod, MD
Tessa Laubscher, MD
George L. Bakris, MD
Mikhail Kosiborod, MD
- Sharing international experience in CKD & SGLT2i: How to identify the right patient at the right moment?Initiation of SGLT2i in CKD: how, when and who?
David Cherney, MD, PhD
Roberto Pecoits-Filho, MD, PhD
Magdalena Madero, MD
- Sharing international experience in CKD & SGLT2i: How to identify the right patient at the right moment?Meta-analysis of the effects of SGLT2i on kidney outcomes
Natalie Staplin, PhD
- Sharing international experience in CKD & SGLT2i: How to identify the right patient at the right moment?SGLT2i in the spectrum of CKD: A call for action
Meg Jardine, MD, PhD
- ESC Heart Failure 2023Benefits of rapid uptitration of HF medications independent of baseline renal function
Jozine ter Maaten, MD, PhD
- Sharing international experience in CKD & SGLT2i: How to identify the right patient at the right moment?The latest evidence of SGLT2i in CKD
Will Herrington, MD
